Sagen MI Canada Management Commentary: Higher Investment Income Drives Q3 2026 Net Income Growth
Bitget2026/11/05 23:56- Sagen MI Canada's management commentary reported third-quarter 2026 net income of CAD 123 million, up 3% year over year.
- Management attributed earnings growth primarily to higher investment income and lower operating expenses, partly offset by weaker insurance results.
- Claims losses rose to CAD 34 million from CAD 14 million, driven by higher net delinquencies and severity amid softer housing conditions.
- Net operating income fell 9% to CAD 116 million, excluding after-tax investment, derivative and foreign exchange gains.
- Nine-month net income declined 3% to CAD 349 million, primarily reflecting weaker insurance service results and higher insurance finance expenses.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Crypto prices
More
